Advertisement

Treatment of Chronic Hand Eczema: Other Immunomodulating Therapies

  • Rodrigo da Mota
  • Bernhard HomeyEmail author
Reference work entry

Abstract

The management of chronic hand eczema is challenging and includes several behavioral and medical measures. A subset of patient will not respond to topical treatment strategies alone, but may benefit from systemic therapy. In this chapter, selected immunomodulating drugs (azathioprin, cyclosporine, methotrexate) which have been successfully used for the systemic treatment of chronic hand eczema is reviewed regarding their clinical pharmacology, mechanisms of action, efficacy, and safety.

Keywords

Chronic hand eczema Immunomodulating drugs Methotrexate Cyclosporine A Azathioprine 

References

  1. Anstey AV, Wakelin S, Reynolds NJ (2004) British Association of Dermatologists Therapy G, Audit S. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151(6):1123–1132CrossRefGoogle Scholar
  2. Granlund H, Erkko P, Eriksson E, Reitamo S (1996) Comparison of cyclosporine and topical betamethasone-17, 21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 76(5):371–376PubMedGoogle Scholar
  3. Griffiths CE, Katsambas A, Dijkmans BA et al (2006) Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 155(Suppl 2):1–16CrossRefGoogle Scholar
  4. Levy LL, Urban J, King BA (2015) Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 73(3):395–399CrossRefGoogle Scholar
  5. Longo-Sorbello GS, Bertino JR (2001) Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86(2):121–127PubMedGoogle Scholar
  6. Lyakhovitsky A, Barzilai A, Heyman R et al (2010) Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 24(1):43–49CrossRefGoogle Scholar
  7. Morabito L, Montesinos MC, Schreibman DM et al (1998) Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 101(2):295–300CrossRefGoogle Scholar
  8. Mrowietz U, Klein CE, Reich K et al (2009) Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges 7(5):474–479PubMedGoogle Scholar
  9. Sahasranaman S, Howard D, Roy S (2008) Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64(8):753–767CrossRefGoogle Scholar
  10. Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348CrossRefGoogle Scholar
  11. Thomas CW, Myhre GM, Tschumper R et al (2005) Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 312(2):537–545CrossRefGoogle Scholar
  12. Verma KK, Bansal A, Sethuraman G (2006) Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol 72(1):24–27CrossRefGoogle Scholar
  13. Verma KK, Mahesh R, Srivastava P, Ramam M, Mukhopadhyaya AK (2008) Azathioprine versus betamethasone for the treatment of parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol 74(5):453–457CrossRefGoogle Scholar
  14. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ (2007) An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 156(2):346–351CrossRefGoogle Scholar
  15. Wise M, Callen JP (2007) Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 20(4):206–215CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of DermatologyUniversity Hospital DuesseldorfDuesseldorfGermany

Personalised recommendations